ABSTRACT
BACKGROUND: Clinical debriefing (CD) improves patient safety and builds team resilience. PURPOSE: We describe the current use of CD by multiprofessional Spanish cardiology team members. METHODS: A self-administered survey exploring 31 items was disseminated online in October 2020. A comparison was made between respondents that who experience in CD with inexperienced respondents. Inferential analysis was done using Pearson's χ 2 test. RESULTS: Out of 167 valid responses, 45.5% had been completed by cardiology nurses. One-third of the respondents had experience in CD. Most common situations preceding CD were those with negative outcomes (81.8%). Time constraint was the most commonly reported barrier (76.3%); however, it was significantly less than the expectation of inexperienced respondents (92%, P < .01). Overall, only 28.2% reported self-confidence in their skills to lead a CD. CONCLUSIONS: There is a necessity in Spanish cardiology teams to receive training in CD and embed it in their daily practice.
Subject(s)
Cardiology , Clinical Competence , Humans , Patient Care Team , Patient Safety , Spain , Surveys and QuestionnairesABSTRACT
No disponible
Subject(s)
Humans , Heart Diseases/diagnosis , Simulation Training/methods , Cardiovascular Diseases/diagnosis , Education, Medical/trends , High Fidelity Simulation Training/methods , Learning/classification , Internship and Residency/methodsABSTRACT
Los fármacos vasoactivos poseen propiedades inotrópicas y vasomotoras. La variabilidad de su respuesta se explica por múltiples factores relacionados con la dosis empleada, la densidad, la afinidad y la selectividad de sus receptores, así como por las complejas vías de señalización. Su indicación no solo debería recaer en un umbral de presión arterial recomendado, sino también en parámetros objetivos de microcirculación. Hasta el momento no se ha demostrado que ningún fármaco vasoactivo aumente la supervivencia, y la crítica más importante es por los graves efectos adversos. Las líneas de investigación se han centrado en la búsqueda de fármacos más selectivos intentando evitar estos efectos adversos y no solo buscando la mejoría sintomática y hemodinámica a corto plazo (AU)
Vasoactive drugs can have inotropic or vasomotor properties or both. Variability in responses to these drugs can be explained by factors related to the dose used, the drugs affinity for specific receptors, the density and selectivity of these receptors, and the operation of complex signaling pathways. Indications for their use should not be based solely on recommended blood pressure thresholds but should also take into account objective microcirculatory parameters. To date, no vasoactive drug has been shown to increase survival, and the main criticism of their use is that they produce serious adverse effects. Research has focused on finding more selective compounds that will avoid these adverse effects and has not only sought to achieve short-term improvements in symptoms and hemodynamics (AU)
